Redx Pharma is a clinical-stage biotechnology company that specializes in the discovery and development of targeted medicines for the treatment of fibrotic disease and cancer. With a focus on cancer-associated fibrosis, Redx aims to transform patients' lives by delivering better medicines faster. Their pipeline includes a range of novel compounds, including zelasudil (RXC007), a next-generation selective ROCK2 inhibitor for multiple interstitial lung diseases and cancer-associated fibrosis, and RXC004, a Porcupine inhibitor for Wnt-ligand dependent tumors.

Additionally, Redx has a robust research program and collaborations to drive innovation in oncology and fibrosis. With a team of world-class scientists and a strong foundation in medicinal chemistry and translational science, Redx is well-equipped to discover and develop potentially differentiated compounds against validated targets. Committed to high standards, resilience, teamwork, innovation, and agility, Redx is dedicated to creating world-leading medicines that have the power to transform patients' lives